SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing heightened volatility as investors debate the impact of Michael Burry's recent short report, which argues that Anthropic's rapid enterprise growth poses an existential threat to Palantir's market share. While some community members view the dip as an artificial setup driven by market manipulation or short-term fear, others are growing concerned that Palantir's premium valuation is increasingly difficult to justify in the face of aggressive competition in the AI sector.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors digest the company's latest 13F filing, which reveals a strategic rotation out of mega-cap tech holdings like Amazon into value-oriented names like The New York Times. The community is actively debating the implications of this shift, with many questioning the company's lack of aggressive capital deployment given its massive cash position and recent underperformance relative to the broader market.

Applied Digital Corporation

Applied Digital is currently at the center of intense community discussion ahead of its quarterly earnings release, with investors closely watching for updates on hyperscaler lease contracts and long-term expansion goals. While some participants express caution regarding the company's debt levels and execution timeline, the majority of the community remains focused on the significant growth potential of its high-performance data center infrastructure and the anticipated momentum from future project deals.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is currently surging due to an at-the-market offering and strong community debate over its high valuation versus its growth potential in the AI and silicon photonics sectors. While some investors remain skeptical of the dilution and revenue figures, others view the financing as an opportunistic move to support a massive, long-term ramp in demand from hyperscale customers.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce shares are under intense scrutiny as a record-setting 25 billion dollar accelerated share repurchase program struggles to provide a meaningful lift, fueling skepticism about the stock's near-term recovery. The community remains deeply divided, with some investors betting on a significant long-term rebound driven by the buyback's impact on earnings per share, while others fear that the ongoing software sector selloff and aggressive competition from emerging AI agents are rendering legacy enterprise models obsolete.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as investors rally around the project's technological potential in on-chain automation and its upcoming milestones, including exchange listings and a shift in token utility. The community is actively discussing the stock as an undervalued asset, with many bullish participants comparing its current trajectory to early-stage growth stories while debating the impact of upcoming catalysts and broader market sentiment.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as investors react to the company's acquisition agreement with Garda Therapeutics, which includes an all-cash tender offer and a potential milestone-based CVR. The community is actively debating the valuation of the deal, with some shareholders expressing frustration over the offer price relative to assets and historical expectations, while others view it as a potential opportunity to capture value from a go-shop period or future competitive bids.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

The SQD community is actively discussing the launch of public revenue pools, with many participants debating the potential for long-term utility versus short-term price volatility. While some investors remain cautious about tokenomics and market manipulation, others are highlighting the project's technical progress in blockchain indexing and its strategic integration with the Rezolve AI ecosystem.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion Inc. is trending as investors weigh significant technological validation from industry giants against a period of sharp stock price volatility and downward pressure. Community discourse centers on the company's long-term potential in quantum sensing and defense partnerships, with many users actively debating whether the current pullback offers a strategic accumulation opportunity or signals deeper valuation concerns.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is capturing market attention as the company secures a prime contract to build a national security satellite for Belgian Defence, a milestone that has triggered significant volatility and call option activity. Community sentiment remains mixed as traders monitor the persistent selling pressure from institutional holders while simultaneously celebrating the companys expanding role in defense infrastructure and its involvement in major NASA missions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results PR Newswire LOS ANGELES...

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025...

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for...

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus Armata Pharmaceuticals...

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of +84.62% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?

Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

<ul class="summary-bullets"><li>The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus bacteremia, with no relapses reported.</li><li>H.C. Wainwright reiterated a ‘Buy’ rating and $9 target, saying the results support advancing AP-SA02 into Phase 3 next year.</li><li>Retail traders flooded Stocktwits with bullish posts after the record rally, with some predicting further gains while others expected a share offering.</li></ul>Shares of Armata Pharmaceuticals surged to a record high on Wednesday after the company reported encouraging Phase 2a results for its experimental bacteriophage therapy, AP-SA02, in patients with complicated Staphylococcus aureus bacteremia (SAB), a serious and often life-threatening bloodstream infection.The stock logged its best session on record on Wednesday, surging 103% to close at $7.05, and fell 16% in after-hours trading as investors took profits following the steep rally.Promising Results In Early-Stage TrialThe findings show for the first time, in a randomized trial, that intravenous phage therapy can be efficacious for S. aureus bacteremia.&nbsp;The diSArm study showed that patients treated with AP-SA02 in addition to the best available antibiotic therapy had an 88% clinical response rate at day 12, compared with 58% for placebo. No patients treated with AP-SA02 relapsed or were non-responsive, versus approximately 25% of patients who received&nbsp;a placebo.A total of 42 patients were enrolled in the trial, and about 38% of the cases had infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Armata said that the treatment was well-tolerated with no serious adverse events associated with the drug.The company is looking to move AP-SA02 into a Phase 3 trial in 2026, based on these results, subject to regulatory input from the U.S. Food and Drug Administration.Analyst ViewH.C. Wainwright reaffirmed its ‘Buy’ rating and $9 price target on Armata, representing a 28% upside from the company’s last close. The brokerage said the results, along with supporting in vitro data, provide “strong evidence for the efficacy of its core therapeutic strategy.” The firm said the data support moving the bacteriophage therapy into a pivotal late-stage study next year.Multi-Phage Cocktail Shows Broad Efficacy&nbsp;Armata said AP-SA02, a fixed cocktail of multiple bacteriophages, showed consistent efficacy against both MRSA and methicillin-sensitive S. aureus (MSSA) and was linked to faster infection clearance and shorter hospital stays. The company received $26.2 million in funding from the U.S. Department of Defense through the Medical Technology Enterprise Consortium to support the diSArm study.Stocktwits Traders See Potential Stock Offering&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 26,200% surge in 24-hour message volume.One user said they expected the company to announce a share offering following the surge in its stock price.<stembedurl>https://stocktwits.com/FredDurst/message/633328173</stembedurl>Another user, however, struck an optimistic tone, predicting that the stock could double in value the next day.<stembedurl>https://stocktwits.com/Lifeinlight/message/633324622</stembedurl><a href="https://stocktwits.com/symbol/ARMP">Armata’s stock</a> has&nbsp;rocketed 281% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Armata Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Armata Pharmaceuticals Stock Soars To Record High After Phage Therapy Data In Deadly Infection Trial; Retail Traders Pile In

H.C. Wainwright reiterated a ‘Buy’ rating and $9 target, saying the results support advancing AP-SA02 into Phase 3 next year.

Equity

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Patrick OShaughnessy - @patrick_oshag on X

Citrini - @Citrini7 on X

Bucco Capital - @buccocapital on X

Joe Weisenthal - @TheStalwart on X

The must-watch individual or show that brings entertainment to finance. This award celebrates the content you look forward to daily - bringing a sharp market edge to engaging discussions. 

ARMP
Armata Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARMP News

ARMPArmata Pharmaceuticals Inc